Andronis, L, Goranitis, I, Pirrie, S, Pope, A, Barton, D, Collins, S, Daunton, A, McLaren, D, O'Sullivan, J M, Parker, C, Porfiri, E, Staffurth, J, Stanley, A, Wylie, J, Beesley, S, Birtle, A, Brown, J E, Chakraborti, P, Hussain, S A, Russell, J M, Billingham, L J & James, N D 2017, ' Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer : results from the TRAPEZE trial (ISRCTN 12808747) ', BJU International, vol. 119, no. 4, pp. 522-529 . https://doi.org/10.1111/bju.13549 Andronis, L, Goranitis, I, Pirrie, S, Pope, A, Barton, D, Collins, S, Daunton, A, McLaren, D, O'Sullivan, J M, Parker, C, Porfiri, E, Staffurth, J, Stanley, A, Wylie, J, Beesley, S, Birtle, A, Brown, J E, Chakraborti, P, Hussain, S A, Russell, J M, Billingham, L J & James, N D 2016, ' Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747) ', BJU International . https://doi.org/10.1111/bju.13549
Health Technology Assessment, Vol 20, Iss 53 (2016) James, N, Pirrie, S, Pope, A, Barton, D, Andronis, L, Goranitis, I, Collins, S, McLaren, D, O'Sullivan, J, Parker, C, Porfiri, E, Staffurth, J, Stanley, A, Wylie, J, Beesley, S, Birtle, A, Brown, J, Chakraborti, P, Russell, M & Billingham, L 2016, ' TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer ', Health Technology Assessment, vol. 20, no. 53, pp. 1-288 . https://doi.org/10.3310/hta20530